You need JavaScript to view this

Animal experiments and clinical trials of {sup 166}Ho-chitosan for various cancers

Abstract

{sup 166}Ho is a good therapeutic radionuclide because of its suitable half-life (26.8 hours), high beta energy and 6% gamma ray for imaging. Chitosan is a kind of N-glucosamine with 400 to 500 kD MW, which chelates metal ions and degrades slowly in vivo. As a preclinical studies, we performed cytotoxic effect of {sup 166}Ho-chitosan in a variety of cancer cell lines derived from stomach or ovarian cancer based on MTT assay and HTCA method. To evaluated the absorbed dose to the cavitary wall from {sup 166}Ho-chitosan, intraperitoneal administration of {sup 166}Ho-chitosan in the rat and simulation of energy transfer from the beta particles to the cavity wall using the Monte Carlo code EGS4 was done, and used as a standard for the planning therapy. Intracavitary {sup 166}Ho-chitosan therapy were tried in peritoneal metastatic ovarian and stomach cancers and cystic brain tumors. Intraarterial injection in inoperable primary liver cancer was also tried. As a radiation synovectomy agent, biocompatibility study in the knee joints of rabbits were performed. {sup 166}Ho-chitosan showed synergistic effects with 5-FU or cisplatin in vitro. 97-99% of {sup 166}Ho-chitosan was localized within the peritoneal cavity, and more than 90% of {sup 166}Ho-chitosan was attached to the peritoneal  More>>
Authors:
Lim, Sang Moo; Choi, C W; Kim, E H; Woo, K S; Chung, W S; Lee, J I; Park, S Y; Son, Y S; Lee, S H; Kim, S J; Kim, B G; Kim, J H; Lee, C H [1] 
  1. Korea Cancer Center Hospital, Seoul (Korea, Republic of)
Publication Date:
Jul 01, 1997
Product Type:
Technical Report
Report Number:
KAERI-CM-128/96
Reference Number:
SCA: 550604; 560152; PA: KR-99:000274; EDB-99:026696; SN: 99002059901
Resource Relation:
Other Information: PBD: Jul 1997
Subject:
55 BIOLOGY AND MEDICINE, BASIC STUDIES; 56 BIOLOGY AND MEDICINE, APPLIED STUDIES; HOLMIUM 166; NEOPLASMS; THERAPEUTIC USES; THERAPY; NEUTRON THERAPY; NEUTRON CAPTURE THERAPY; GLUCOSAMINE; IN VIVO; ANIMAL TISSUES; STOMACH; PERITONEUM; LIVER; BRAIN
OSTI ID:
314741
Research Organizations:
Korea Atomic Energy Research Institute, Taejon (Korea, Republic of)
Country of Origin:
Korea, Republic of
Language:
Korean
Other Identifying Numbers:
Other: ON: DE99727850; TRN: KR9900274
Availability:
OSTI as DE99727850
Submitting Site:
KR
Size:
123 p.
Announcement Date:

Citation Formats

Lim, Sang Moo, Choi, C W, Kim, E H, Woo, K S, Chung, W S, Lee, J I, Park, S Y, Son, Y S, Lee, S H, Kim, S J, Kim, B G, Kim, J H, and Lee, C H. Animal experiments and clinical trials of {sup 166}Ho-chitosan for various cancers. Korea, Republic of: N. p., 1997. Web.
Lim, Sang Moo, Choi, C W, Kim, E H, Woo, K S, Chung, W S, Lee, J I, Park, S Y, Son, Y S, Lee, S H, Kim, S J, Kim, B G, Kim, J H, & Lee, C H. Animal experiments and clinical trials of {sup 166}Ho-chitosan for various cancers. Korea, Republic of.
Lim, Sang Moo, Choi, C W, Kim, E H, Woo, K S, Chung, W S, Lee, J I, Park, S Y, Son, Y S, Lee, S H, Kim, S J, Kim, B G, Kim, J H, and Lee, C H. 1997. "Animal experiments and clinical trials of {sup 166}Ho-chitosan for various cancers." Korea, Republic of.
@misc{etde_314741,
title = {Animal experiments and clinical trials of {sup 166}Ho-chitosan for various cancers}
author = {Lim, Sang Moo, Choi, C W, Kim, E H, Woo, K S, Chung, W S, Lee, J I, Park, S Y, Son, Y S, Lee, S H, Kim, S J, Kim, B G, Kim, J H, and Lee, C H}
abstractNote = {{sup 166}Ho is a good therapeutic radionuclide because of its suitable half-life (26.8 hours), high beta energy and 6% gamma ray for imaging. Chitosan is a kind of N-glucosamine with 400 to 500 kD MW, which chelates metal ions and degrades slowly in vivo. As a preclinical studies, we performed cytotoxic effect of {sup 166}Ho-chitosan in a variety of cancer cell lines derived from stomach or ovarian cancer based on MTT assay and HTCA method. To evaluated the absorbed dose to the cavitary wall from {sup 166}Ho-chitosan, intraperitoneal administration of {sup 166}Ho-chitosan in the rat and simulation of energy transfer from the beta particles to the cavity wall using the Monte Carlo code EGS4 was done, and used as a standard for the planning therapy. Intracavitary {sup 166}Ho-chitosan therapy were tried in peritoneal metastatic ovarian and stomach cancers and cystic brain tumors. Intraarterial injection in inoperable primary liver cancer was also tried. As a radiation synovectomy agent, biocompatibility study in the knee joints of rabbits were performed. {sup 166}Ho-chitosan showed synergistic effects with 5-FU or cisplatin in vitro. 97-99% of {sup 166}Ho-chitosan was localized within the peritoneal cavity, and more than 90% of {sup 166}Ho-chitosan was attached to the peritoneal wall. Partial response were observed in 4 among 5 patients with ovarian cancer without severe toxicity. In the cystic brain tumor, 5 of 8 cysts were shrunken in size with thinning of the wall, 2 out of 8 showed growth retardation. In the primary liver cancer, radioactivity was distributed in the teritory of selected hepatic arterial branch, and partial responses were observed in 2 cases. In the knee joints of the rabbits, more than 98% of {sup 166}Ho-chitosan remained in the joint cavity and was stable upto 1 week. 49 refs., 22 tabs. (author)}
place = {Korea, Republic of}
year = {1997}
month = {Jul}
}